Phenylalanine lyase mutant, and conjugate thereof or pharmaceutically acceptable salt thereof

By developing polyethylene glycol-modified phenylalanine lyase mutants, the problem that existing treatment methods cannot effectively reduce phenylalanine levels in the body is solved, effective treatment of phenylalanine is achieved, and drug-related treatment is extended Blood drugs last and reduce the immune response.

WO2024230614A1PCT designated stage expired Publication Date: 2024-11-14CHONGQING PEG BIO BIOTECH CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/091015
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-04-30
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Existing treatments for phenylketonuria such as dietary control therapy and BH4 replacement therapy have limitations and cannot effectively reduce phenylalanine levels in the body, resulting in nervous system damage and quality of life. The existing drugs cannot be treated by phenylalanine. Phenylketonuria caused by hydroxylase deficiency.

Method used

Develop a phenylalanine lyase mutant and its conjugate to improve enzyme activity retention and reduce immunogenicity through polyethylene glycol modification. It is used to prevent and treat phenylketonuria, with a longer blood drug Maintenance time and lower immune response.

Benefits of technology

In PKU model mice, the blood phenylalanine level was significantly reduced, the blood drug maintenance time of the drug was prolonged, the antibody titer was reduced, and the continued efficacy of the treatment and the quality of life of the patients were improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024091015-FTAPPB-I100001
    Figure PCTCN2024091015-FTAPPB-I100001
  • Figure PCTCN2024091015-FTAPPB-I100002
    Figure PCTCN2024091015-FTAPPB-I100002
  • Figure PCTCN2024091015-FTAPPB-I100003
    Figure PCTCN2024091015-FTAPPB-I100003
Patent Text Reader

Abstract

Provided is a phenylalanine lyase mutant. Compared with the amino acid sequence of phenylalanine lyase, the phenylalanine lyase mutant has a mutation at at least one of the following sites: position 72, position 240, position 467 and position 544.
Need to check novelty before this filing date? Find Prior Art

Description

Phenylalanine lyase mutant and conjugate thereof or pharmaceutically acceptable salt thereof Technical Field

[0001] The present invention belongs to the field of biopharmaceutical technology. Specifically, the present invention relates to a phenylalanine lyase mutant and a conjugate thereof or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a phenylalanine lyase mutant, a nucleic acid molecule, an expression vector, a recombinant cell, a phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof, a polyethylene glycol-modified phenylalanine lyase mutant, a pharmaceutical composition and its use, and a method for reducing the immunogenicity of phenylalanine lyase while maintaining the enzymatic activity of phenylalanine lyase. Background Art

[0002] Phenylketonuria (PKU, also known as phenylalanine hydroxylase deficiency) is a recessive genetic disorder of phenylalanine metabolism caused by a deficiency or reduced activity of phenylalanine hydroxylase in the liver. Phenylalanine is an essential amino acid involved in numerous physiological processes, but the body cannot synthesize it and must obtain it through dietary intake. Normally, ingested phenylalanine is used to synthesize various proteins. The remaining phenylalanine is converted to tyrosine by phenylalanine hydroxylase, and then to tyrosine by other enzymes. However, in patients with PKU, the deficiency or reduced activity of phenylalanine hydroxylase (PAH) prevents the effective degradation of phenylalanine. This leads to accumulation of phenylalanine in the patient's plasma. When the plasma phenylalanine concentration exceeds the renal threshold, it is excreted in the urine, resulting in phenylalaninuria. Furthermore, the accumulated phenylalanine is metabolized through other pathways to produce phenylpyruvic acid and phenyllactic acid, substances that are toxic to the brain and other nervous systems.

[0003] This disease is a recessive genetic disorder. After birth, affected children lack phenylalanine hydroxylase (PAH) activity, making it impossible to effectively degrade phenylalanine produced by breastfeeding or the diet. This leads to the accumulation of phenylpyruvate and other substances that are toxic to the nervous system. This, in turn, affects the development of the brain and other nervous systems, leading to severe intellectual impairment with age and other abnormal behaviors, such as epilepsy. Impaired phenylalanine metabolism, caused by impaired PAH activity in the liver, can lead to phenylketonuria (PKU) and hyperphenylalaninemia (HPA), manifesting as impaired neurophysiological function and decreased cognitive development. If a pregnant woman with PKU develops PKU, the child will begin to experience neurological damage in the womb.

[0004] Currently, there are three main treatments for phenylketonuria: diet control therapy, BH4 (tetrahydrobiopterin) replacement therapy, and drug therapy.

[0005] Dietary control therapy reduces the accumulation of phenylalanine and phenylpropion in plasma by lowering the phenylalanine content in the patient's diet, while also supplementing with serotonin and L-dopamine. While this approach can provide some control, long-term patient compliance and quality of life are difficult to guarantee. Furthermore, it cannot eliminate the neurological effects of elevated phenylalanine levels. Dietary control during pregnancy can also lead to birth defects in the fetus, and the lack of certain nutrients during dietary therapy can also be detrimental to brain development.

[0006] BH4 replacement therapy reduces phenylalanine levels in the body by administering physiological doses of BH4, but it is not effective for all patients. Currently, there are only two such drugs for the treatment of phenylketonuria, marketed by Biomarin and Suntory. Both are for heterotypic hyperphenylpropionic acidemia (i.e., hyperphenylpropionic acidemia caused by deficiency of dihydropterin reductase or synthase), and cannot treat phenylketonuria caused by phenylalanine hydroxylase deficiency.

[0007] Therefore, there is an urgent need to develop a drug that can effectively treat high-phenylalanine-related diseases such as phenylketonuria.

[0008] Summary of the Invention

[0009] The present invention aims to, at least to some extent, address at least one of the technical problems existing in the prior art. To this end, the present invention provides a phenylalanine lyase mutant conjugate, which exhibits advantages such as low immunogenicity and a long in vivo half-life and can be used to prevent and treat high-phenylalanine-related diseases such as phenylketonuria.

[0010] The present invention is accomplished based on the following findings of the inventors:

[0011] Phenylalanine lyase is a non-mammalian enzyme found widely in plants (e.g., Rhodotorula tomentosa, Rhodotorula crimsonii, potato, wheat, lichens, Streptomyces, and Anabaena variabilis). Its active form is a homotetramer that converts phenylalanine into trans-cinnamic acid and ammonia, which is then metabolized to hippuric acid and excreted in the urine. As early as the late 1990s, researchers used Rhodotorula tomentosa phenylalanine lyase to reduce plasma phenylalanine levels in mice through subcutaneous or oral administration. However, phenylalanine lyases derived from microorganisms or plants are rapidly inactivated by immune responses upon entry into the human body. Furthermore, they are unstable in the human body and are easily degraded by proteolytic enzymes, resulting in loss of activity.

[0012] In the PKU model mouse treatment experiment, wild-type PAL proteins from four different sources, including RhPAL from Rhodotorula toruloides, NpPAL from Coccidioides punctata, PcPAL from Pteris multiflora, and AvPAL from Anabaena variabilis, were tested. RhPAL and AvPAL and their PEGylated conjugates were considered more suitable for the treatment of PKU mice because they had the highest enzyme specific activity and advantages in optimal reaction pH, Km parameters, protease resistance and thermal stability. It is speculated that this may be related to the number of amino acids carried by their wild-type sequences and molecular properties.

[0013] Results from a Phase III clinical study of the marketed PEGVALIASE drug showed that among 261 participants treated with PEGVALIASE, 72.0% and 32.6% achieved study endpoints of ≥12 months and ≥24 months, respectively, with 65% remaining on treatment. Within 24 months, 68.4% of participants achieved blood Phe ≤600 μmol / L, 60.7% achieved blood Phe ≤360 μmol / L, and 51.2% achieved blood Phe ≤120 μmol / L. While serum Phe levels were temporarily effectively controlled during dosing, anti-PAL IgM / IgG antibody titers gradually increased with increasing dosing frequency, leading to drug clearance from the blood, necessitating increased dosing doses and frequency to maintain efficacy.

[0014] However, in one aspect of the present invention, a phenylalanine lyase mutant is provided. According to an embodiment of the present invention, compared with the amino acid sequence of phenylalanine lyase, the phenylalanine lyase mutant has mutations at at least one of positions 72, 240, 467, and 544. By mutating the above-mentioned specific sites of phenylalanine lyase, the phenylalanine lyase mutant obtained by polyethylene glycol modification can increase the average degree of polyethylene glycol modification, improve the enzyme activity retention rate, reduce immunogenicity, and maintain blood drug levels for 5 to 7 days.

[0015] In another aspect, the present invention provides a nucleic acid molecule encoding the aforementioned phenylalanine lyase mutant according to an embodiment of the present invention, and the nucleic acid molecule encoding the aforementioned phenylalanine lyase mutant according to an embodiment of the present invention.

[0016] In yet another aspect, the present invention provides an expression vector. According to an embodiment of the present invention, the expression vector carries the aforementioned nucleic acid molecule. The expression vector according to an embodiment of the present invention can effectively express the aforementioned phenylalanine lyase mutant, thereby enabling the in vitro production of large quantities of the phenylalanine lyase mutant.

[0017] In yet another aspect, the present invention provides a recombinant cell. According to an embodiment of the present invention, the recombinant cell comprises: carrying the aforementioned nucleic acid molecule or expression vector; or expressing the aforementioned phenylalanine lyase mutant. Under suitable conditions, the recombinant cell can effectively express the aforementioned phenylalanine lyase mutant within the cell.

[0018] In another aspect, the present invention provides a phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof. According to an embodiment of the present invention, the phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof comprises: the aforementioned phenylalanine lyase mutant; and a modifying group attached to the phenylalanine lyase mutant. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof of the present invention has advantages such as a high average degree of polyethylene glycol modification, high enzyme activity retention, low immunogenicity, and prolonged blood drug retention.

[0019] In another aspect of the present invention, the present invention provides a polyethylene glycol-modified phenylalanine lyase mutant. According to an embodiment of the present invention, at least the following amino acid sites in the phenylalanine lyase mutant are PEG-modified: K 72 , K 240 , K 467 and K 544 The polyethylene glycol-modified phenylalanine lyase mutant of the present invention has the advantages of high average modification degree, high enzyme activity retention rate, low immunogenicity and long blood drug maintenance time.

[0020] In yet another aspect, the present invention provides a pharmaceutical composition. According to an embodiment of the present invention, the pharmaceutical composition comprises: the aforementioned phenylalanine lyase mutant or the aforementioned phenylalanine lyase mutant conjugate, or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention is effective for preventing and / or treating diseases associated with high phenylalanine levels, particularly for treating phenylketonuria.

[0021] In another aspect of the present invention, the present invention provides a use of the aforementioned phenylalanine lyase mutant, the aforementioned phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof, the aforementioned polyethylene glycol-modified phenylalanine lyase mutant or the aforementioned pharmaceutical composition in the preparation of a drug for preventing and / or treating high phenylalanine-related diseases.

[0022] In another aspect, the present invention provides a method for reducing the immunogenicity of phenylalanine lyase while maintaining the enzymatic activity of the enzyme. According to an embodiment of the present invention, the method comprises: PEG-modifying the mutation site of the mutated phenylalanine lyase; the mutation site comprises at least one of E72K, Q240K, R467K, and R544K. The method of the present invention can reduce the immunogenicity of the phenylalanine lyase while maintaining a high retention rate of the phenylalanine lyase activity.

[0023] Additional aspects and advantages of the present invention will be set forth in part in the description which follows and, in part, will be obvious from the description which follows, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the following description of the embodiments with reference to the accompanying drawings, in which:

[0025] FIG1 is the SDS-PAGE purity analysis result of the phenylalanine lyase mutant in Example 2 of the present invention;

[0026] FIG2 is the SEC-HPLC purity analysis result of the phenylalanine lyase mutant in Example 2 of the present invention;

[0027] FIG3 is the result of analysis of modification sites of phenylalanine lyase mutant directed conjugates in Example 4 of the present invention;

[0028] FIG4 shows the changes in blood drug content of polyethylene glycol conjugates of phenylalanine lyase and its mutants with different average modification degrees in Example 5 of the present invention after multiple administration in rats;

[0029] Figure 5 shows the changes in Anti-PEG-IgM / IgG antibody titers (A) and Anti-PAL-IgG antibody titers (B) in serum of rats after multiple administration of the polyethylene glycol conjugate of the phenylalanine lyase mutant in Example 5 of the present invention;

[0030] FIG6 is a polyethylene glycol conjugate of the phenylalanine lyase mutant in Example 7 of the present invention - Pah enu Changes in serum phenylalanine concentrations in mice after multiple administration of different doses;

[0031] FIG. 7 is a polyethylene glycol conjugate of the phenylalanine lyase mutant in Example 7 of the present invention - Pah enu Changes in blood drug concentrations after multiple administration of different doses to mice;

[0032] FIG8 is a polyethylene glycol conjugate of the phenylalanine lyase mutant in Example 7 of the present invention - Pah enu Anti-PEG IgG antibody titers in mice after multiple administration of different doses;

[0033] FIG9 is a polyethylene glycol conjugate of the phenylalanine lyase mutant in Example 7 of the present invention - Pah enu Anti-PEG IgM antibody titers in mice after multiple administration of different doses;

[0034] FIG10 is a single-dose pharmacokinetic curve of the polyethylene glycol conjugate of the phenylalanine lyase mutant in Example 9 of the present invention in Beagle dogs;

[0035] FIG. 11 is a polyethylene glycol conjugate of the phenylalanine lyase mutant in Example 10 of the present invention and Pegvaliase-Pah enu Changes in serum phenylalanine concentrations in mice after multiple dosing;

[0036] FIG. 12 shows the polyethylene glycol conjugate of the phenylalanine lyase mutant in Example 10 of the present invention and the Pegvaliase-Pah enu Anti-PEG IgG and IgM antibody titers in mice after multiple dosing trials. DETAILED DESCRIPTION

[0037] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.

[0038] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of the technical features indicated. Therefore, features defined as "first" or "second" may explicitly or implicitly include one or more of such features. Furthermore, in the description of the present invention, unless otherwise specified, "plurality" means two or more.

[0039] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention, but not excluding other contents.

[0040] As used herein, the terms "optionally," "optional," or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0041] As used herein, the terms "identity," "homology," or "similarity" are used to describe an amino acid sequence or nucleic acid sequence relative to a reference sequence, and the percentage of identical amino acids or nucleotides between two amino acid sequences or nucleic acid sequences is determined by conventional methods, for example, see Ausubel et al., eds. (1995), Current Protocols in Molecular Biology, Chapter 19 (Greene Publishing and Wiley-Interscience, New York); and the ALIGN program (Dayhoff (1978), Atlas of Protein Sequence and Structure 5: Suppl. 3 (National Biomedical Research Foundation, Washington, DC). There are many algorithms for aligning sequences and determining sequence identity, including the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol. 48:443; the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482; the similarity search method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 85:2444; the Smith-Waterman algorithm (Meth. Mol. Biol. 10:106); the similarity search method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 10:116; the similarity search method of Pearson et al. (1990) Proc. Natl. Acad. Sci. 10:117; the similarity search method of Pearson et al. (1990 ... .70:173-187 (1997); and BLASTP, BLASTN, and BLASTX algorithms (see Altschul et al. (1990) J. Mol. Biol. 215:403-410). Computer programs that utilize these algorithms are also available and include, but are not limited to, ALIGN or Megalign (DNASTAR) software, or WU-BLAST-2 (Altschul et al., Meth. Enzym., 266:460-480 (1996)); or GAP, BESTFIT, BLAST Altschul et al., supra, FASTA, and TFASTA, available in the Genetics Computing Group (GCG) package, Version 8, Madison, Wisconsin, USA; and CLUSTAL in the PC / Gene program provided by Intelligenetics, Mountain View, California.

[0042] As used herein, the term "at least 50% homology" refers to at least 50%, and can be 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% homology to the respective reference sequence. The term "at least 90% homology" refers to at least 90%, which can be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% homology to the respective reference sequence.

[0043] As used herein, the term "pharmaceutical composition" generally refers to a unit dosage form and can be prepared by any of the methods well known in the pharmaceutical art. All methods include the step of combining the active ingredient with a carrier that constitutes one or more accessory ingredients. Generally, the pharmaceutical composition is prepared by uniformly and thoroughly combining the active phenylalanine lyase mutant, phenylalanine lyase mutant conjugate, or a pharmaceutically acceptable salt thereof with a liquid carrier, a finely divided solid carrier, or both.

[0044] As used herein, the term "pharmaceutically acceptable excipient" includes any solvent, solid excipient, diluent, or other liquid excipient, etc., suitable for the specific intended dosage form. In addition to any conventional excipients, excipients that are incompatible with the phenylalanine lyase mutants, phenylalanine lyase mutant conjugates, or pharmaceutically acceptable salts thereof of the present invention, such as those that may produce any adverse biological effects or that may interact in a deleterious manner with any other component of the pharmaceutical composition, are also contemplated for use in the present invention.

[0045] As used herein, the term "administer" refers to the introduction of a predetermined amount of a substance into a patient by a suitable means. The phenylalanine lyase mutant, phenylalanine lyase mutant conjugate, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions of the present invention can be administered by any common route, as long as it can reach the intended tissue. Various modes of administration are contemplated, including peritoneal, intravenous, intramuscular, subcutaneous, and the like, but the present invention is not limited to these exemplified modes of administration. Preferably, the phenylalanine lyase mutant, phenylalanine lyase mutant conjugate, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions of the present invention are administered by intravenous or subcutaneous injection.

[0046] As used herein, the term "treatment" refers to any agent used to obtain a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as arresting the progression of the disease; or (c) alleviating the disease, such as alleviating the symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a phenylalanine lyase mutant, a phenylalanine lyase mutant conjugate, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, or a drug to an individual to treat, cure, alleviate, improve, mitigate, or inhibit the individual's disease, including but not limited to administering a drug described herein to an individual in need.

[0047] As used herein, the term "cancer" or "tumor" may be any unregulated cell growth. Exemplary cancers include non-small cell lung cancer, papillary thyroid cancer, glioblastoma multiforme, colon cancer, rectal cancer, lung cancer, head and neck cancer, kidney cancer, bladder cancer, breast cancer, ovarian cancer, liver cancer, bile duct cancer, or sarcoma, acute myeloid leukemia, large cell neuroendocrine carcinoma, neuroblastoma, prostate cancer, neuroblastoma, pancreatic cancer, melanoma, head and neck squamous cell carcinoma, cervical cancer, skin cancer, glioma, esophageal cancer, oral squamous cell carcinoma, or gastric cancer, among others.

[0048] The present invention provides a phenylalanine lyase mutant, a nucleic acid molecule, an expression vector, a recombinant cell, a phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof, a polyethylene glycol-modified phenylalanine lyase mutant, a pharmaceutical composition and its use, and a method for reducing the immunogenicity of phenylalanine lyase while maintaining the enzymatic activity of phenylalanine lyase, each of which will be described in detail below.

[0049] Phenylalanine lyase mutant

[0050] In one aspect, the present invention provides a phenylalanine lyase mutant. According to an embodiment of the present invention, compared with the amino acid sequence of phenylalanine lyase, the phenylalanine lyase mutant has the following mutation sites: at least one of positions 72, 240, 467, and 544. By mutating the aforementioned specific sites of phenylalanine lyase, the resulting phenylalanine lyase mutant, after polyethylene glycol modification, can increase the average degree of polyethylene glycol modification, improve enzyme activity retention, reduce immunogenicity, and maintain blood drug activity for 5 to 7 days.

[0051] According to an embodiment of the present invention, the phenylalanine lyase mutant may further include at least one of the following technical features:

[0052] According to an embodiment of the present invention, the mutation site is located based on the amino acid sequence shown in SEQ ID NO: 1.

[0053] According to an embodiment of the present invention, the phenylalanine lyase has an amino acid sequence as shown in SEQ ID NO: 2-3 or an amino acid sequence having at least 50% homology thereto.

[0054] The amino acid sequences shown in SEQ ID NOs: 1 and 2 are phenylalanine lyases derived from Anabaena variabilis or variants thereof, and the amino acid sequence shown in SEQ ID NO: 3 is phenylalanine lyases derived from Nostoc punctata.

[0055] It should be noted that the location of the mutation sites in the present invention is based on the amino acid sequence set forth in SEQ ID NO: 1. For example, position 72 refers to the amino acid at position 72 based on the amino acid sequence set forth in SEQ ID NO: 1; position 240 refers to the amino acid at position 240 based on the amino acid sequence set forth in SEQ ID NO: 1; position 467 refers to the amino acid at position 467 based on the amino acid sequence set forth in SEQ ID NO: 1; and position 544 refers to the amino acid at position 544 based on the amino acid sequence set forth in SEQ ID NO: 1. The mutation sites of the amino acid sequences set forth in SEQ ID NOs: 2 to 3 can be determined based on homology comparison with SEQ ID NO: 1, for example, homology comparison can be determined by the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol. 48: 443, the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2: 482, or the like.

[0056] Illustratively, the phenylalanine lyase mutant includes: a phenylalanine lyase mutant having at least one mutation site among positions 72, 240, 467 and 544 compared to the amino acid sequence shown in SEQ ID NO:1.

[0057] Illustratively, the phenylalanine lyase mutant includes: a phenylalanine lyase mutant having at least one mutation site among positions 72, 240, 467 and 544 compared to the amino acid sequence shown in SEQ ID NO: 2.

[0058] Illustratively, the phenylalanine lyase mutant includes: a phenylalanine lyase mutant having at least one mutation site among positions 72, 467 and 544 compared to the amino acid sequence shown in SEQ ID NO:3.

[0059] According to an embodiment of the present invention, the mutation site of the phenylalanine lyase mutant is an amino acid that can bind to a modifying group.

[0060] According to an embodiment of the present invention, the amino acid capable of binding to a modifying group is lysine.

[0061] According to an embodiment of the present invention, the mutation site of the phenylalanine lyase mutant is selected from amino acid sites with ASA≥60% or RSA≥30%.

[0062] According to an embodiment of the present invention, the mutation site of the phenylalanine lyase mutant is selected from an amino acid site with a pKa>9.0.

[0063] According to an embodiment of the present invention, the phenylalanine lyase mutant comprises at least one of the mutation sites E72K, Q240K, R467K, and R544K, compared to the amino acid sequence shown in any one of SEQ ID NOs: 1-2. Thus, the average degree of polyethylene glycol modification, the enzyme activity retention rate, and the immunogenicity of the phenylalanine lyase mutant can be increased.

[0064] It should be noted that “including at least one of E72K, Q240K, R467K and R544K” means that in addition to at least one of the above four mutation sites, the phenylalanine lyase mutant of the present invention may further include other mutation sites.

[0065] According to an embodiment of the present invention, the phenylalanine lyase mutant includes at least one of the mutation sites E72K, R467K, and R544K compared to the amino acid sequence shown in SEQ ID NO: 3. Thus, the average degree of polyethylene glycol modification, the enzyme activity retention rate, and the immunogenicity of the phenylalanine lyase mutant can be increased.

[0066] According to an embodiment of the present invention, compared to the amino acid sequence shown in any one of SEQ ID NOs: 1 to 2, the phenylalanine lyase mutant has the following mutation sites: 1) R467K and R544K; or, 2) E72K, R467K, and R544K; or, 3) E72K, Q240K, R467K, and R544K. This can further improve the average degree of polyethylene glycol modification, enzyme activity retention, and immunogenicity of the phenylalanine lyase mutant.

[0067] According to an embodiment of the present invention, compared with the amino acid sequence shown in SEQ ID NO: 3, the phenylalanine lyase mutant has the following mutation sites: 1) R467K and R544K; or, 2) E72K, R467K and R544K.

[0068] According to an embodiment of the present invention, the phenylalanine lyase mutant has an amino acid sequence as shown in any one of SEQ ID NOs: 4 to 11, or an amino acid sequence having at least 50% homology thereto. Thus, the average degree of polyethylene glycol modification, the enzyme activity retention rate, and the immunogenicity of the phenylalanine lyase mutant can be further improved.

[0069] Nucleic acid molecules, expression vectors and recombinant cells

[0070] In another aspect, the present invention provides a nucleic acid molecule encoding the aforementioned phenylalanine lyase mutant according to an embodiment of the present invention, and the nucleic acid molecule encoding the aforementioned phenylalanine lyase mutant according to an embodiment of the present invention.

[0071] According to an embodiment of the present invention, the nucleic acid molecule is DNA.

[0072] It should be noted that, for the nucleic acid molecules mentioned in the present invention, those skilled in the art will understand that they actually include either or both of the complementary double strands. For convenience, although only one strand is provided in most cases in the present invention, the other complementary strand is also disclosed. In addition, the nucleic acid sequences in the present invention include DNA or RNA forms, and disclosure of one form implies disclosure of the other.

[0073] In another aspect of the present invention, the present invention proposes an expression vector. According to an embodiment of the present invention, it carries the aforementioned nucleic acid molecule. When the aforementioned nucleic acid molecule is connected to the vector, the nucleic acid molecule can be directly or indirectly connected to the control elements on the vector, as long as these control elements can control the translation and expression of the nucleic acid molecule. Of course, these control elements can come directly from the vector itself, or they can be exogenous, that is, not from the vector itself. Of course, the nucleic acid molecule can be operably connected to the control elements. In this article, "operably connected" means connecting the exogenous gene to the vector so that the control elements in the vector, such as transcription control sequences and translation control sequences, etc., can play their expected function of regulating the transcription and translation of the exogenous gene. Commonly used vectors can be, for example, plasmids, phages, etc. After the expression vector according to some specific embodiments of the present invention is introduced into a suitable recipient cell, the expression of the aforementioned phenylalanine lyase mutant can be effectively achieved under the mediation of the regulatory system, thereby achieving large-scale in vitro acquisition of the phenylalanine lyase mutant.

[0074] According to an embodiment of the present invention, the expression vector is a eukaryotic expression vector, a prokaryotic expression vector, a virus or a bacteriophage.

[0075] According to an embodiment of the present invention, the expression vector is a lentiviral expression vector.

[0076] In yet another aspect, the present invention provides a recombinant cell. According to an embodiment of the present invention, the recombinant cell comprises: carrying the aforementioned nucleic acid molecule or expression vector; or expressing the aforementioned phenylalanine lyase mutant. Under suitable conditions, the recombinant cell can effectively express the aforementioned phenylalanine lyase mutant within the cell.

[0077] According to an embodiment of the present invention, the recombinant cell is obtained by introducing the aforementioned expression vector into a host cell.

[0078] Phenylalanine lyase mutant conjugate or pharmaceutically acceptable salt thereof

[0079] In another aspect, the present invention provides a phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof. According to an embodiment of the present invention, the phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof comprises: the aforementioned phenylalanine lyase mutant; and a modifying group attached to the phenylalanine lyase mutant. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof of the present invention has advantages such as a high average degree of polyethylene glycol modification, high enzyme activity retention, low immunogenicity, and prolonged blood drug retention.

[0080] According to an embodiment of the present invention, the modifying group is polyethylene glycol.

[0081] According to an embodiment of the present invention, the molecular weight of the polyethylene glycol is 2 to 40 KDa, for example, 2 to 10 KDa or 5 to 20 KDa, thereby increasing the antibody titer after multiple administrations.

[0082] According to an embodiment of the present invention, the polyethylene glycol is a linear polyethylene glycol or a branched polyethylene glycol.

[0083] According to an embodiment of the present invention, the polyethylene glycol has a monomethoxy group or a hydroxyl group.

[0084] According to an embodiment of the present invention, the polyethylene glycol is polyethylene glycol having an active group.

[0085] According to an embodiment of the present invention, the active group of the polyethylene glycol includes at least one of succinimidyl butyrate, succinimidyl propionate, succinimidyl acetate, succinimidyl carbonate and nitrobenzene carbonate, preferably succinimidyl propionate.

[0086] According to an embodiment of the present invention, the modifying group and the lysine of the phenylalanine lyase mutant are coupled via an amide bond.

[0087] According to an embodiment of the present invention, the coupling rate of lysine modified by the modifying group in the phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof is not less than 50%.

[0088] According to an embodiment of the present invention, the coupling rate of lysine at the mutation site in the phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof modified by the modifying group is not less than 80%.

[0089] According to an embodiment of the present invention, the molar ratio of the modifying group to the phenylalanine lyase mutant is (5-20):1, for example, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1 and 20:1, and a range value between any two molar ratios, for example, 8:1 to 20:1.

[0090] According to an embodiment of the present invention, the peptide map of the phenylalanine lyase mutant conjugate has peptide segments with reduced peak areas as shown in Table 4.

[0091] According to an embodiment of the present invention, the peptide map of the phenylalanine lyase mutant conjugate is shown in FIG3 .

[0092] Polyethylene glycol-modified phenylalanine lyase mutant and preparation method thereof

[0093] In another aspect of the present invention, the present invention provides a polyethylene glycol-modified phenylalanine lyase mutant. According to an embodiment of the present invention, at least the following amino acid sites in the phenylalanine lyase mutant are PEG-modified: K 72 , K 240 , K 467 and K 544 The polyethylene glycol-modified phenylalanine lyase mutant of the present invention has the advantages of high average modification degree, high enzyme activity retention rate, low immunogenicity and long blood drug maintenance time.

[0094] In this article, “K 72 ” means that the amino acid site for PEG modification in the phenylalanine lyase mutant is lysine at position 72 of the phenylalanine lyase mutant.

[0095] According to an embodiment of the present invention, the phenylalanine lyase mutant is the phenylalanine lyase mutant defined above.

[0096] According to an embodiment of the present invention, the phenylalanine lyase mutant has an amino acid sequence as shown in any one of SEQ ID NOs: 4 to 11 or an amino acid sequence having at least 50% homology thereto.

[0097] It should be noted that the positioning of the mutation sites in the present application is based on the amino acid sequences shown in SEQ ID NO: 1 and SEQ ID NO: 6. For example, position 72 refers to the amino acid at position 72 based on the amino acid sequence shown in SEQ ID NO: 6; position 240 refers to the amino acid at position 240 based on the amino acid sequence shown in SEQ ID NO: 6; position 467 refers to the amino acid at position 467 based on the amino acid sequence shown in SEQ ID NO: 6; position 544 refers to the amino acid at position 544 based on the amino acid sequence shown in SEQ ID NO: 6. Among them, the mutation sites of the amino acid sequences shown in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NOs:7 to 11 can be determined based on homology comparison with SEQ ID NO:6. For example, homology comparison can be determined by the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol. 48:443, the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482, etc.

[0098] According to an embodiment of the present invention, K in the phenylalanine lyase mutant shown in SEQ ID NO: 4 467 and K 544 With PEG modification.

[0099] According to an embodiment of the present invention, K in the phenylalanine lyase mutant shown in SEQ ID NO: 5 72 , K 467 and K 544 With PEG modification.

[0100] According to an embodiment of the present invention, K in the phenylalanine lyase mutant shown in SEQ ID NO: 6 72 , K 240 , K 467 and K 544 With PEG modification.

[0101] According to an embodiment of the present invention, K in the phenylalanine lyase mutant shown in SEQ ID NO: 7 467 and K 544 With PEG modification.

[0102] According to an embodiment of the present invention, K in the phenylalanine lyase mutant shown in SEQ ID NO: 8 72 , K 467 and K 544 With PEG modification.

[0103] According to an embodiment of the present invention, K in the phenylalanine lyase mutant shown in SEQ ID NO: 9 72 , K 240 , K 467 and K 544 With PEG modification.

[0104] According to an embodiment of the present invention, K in the phenylalanine lyase mutant shown in SEQ ID NO: 10 467 and K 544 With PEG modification.

[0105] According to an embodiment of the present invention, K in the phenylalanine lyase mutant shown in SEQ ID NO: 11 72 , K 467 and K 544 With PEG modification.

[0106] In a preferred embodiment of the present invention, the phenylalanine lyase mutant has an amino acid sequence as shown in any one of SEQ ID NO: 6 and SEQ ID NO: 8.

[0107] As described herein, the polyethylene glycol-modified phenylalanine lyase mutant of the present invention is obtained by covalently modifying the phenylalanine lyase mutant with polyethylene glycol. The polyethylene glycol (PEG) refers to a mixture of ethylene oxide condensation product and water, which has the general formula H(OCH2CH2)n OH said that this is a pH-neutral, non-toxic, highly water-soluble hydrophilic polymer with a linear or branched structure. Due to PEG's non-toxicity and good biocompatibility, the FDA has approved the marketing of a variety of PEG-modified recombinant protein drugs, proving that PEG can be used to reduce the immunogenicity of proteins, increase protein solubility, and extend protein half-life. In order for PEG to bind to proteins, one or more ends of the PEG must be activated. The corresponding modification group can be selected for activation based on the target protein, such as amino, sulfhydryl, carboxyl, or hydroxyl groups.

[0108] In some optional embodiments of the present invention, the site for PEG modification in the phenylalanine lyase mutant of the present invention is the epsilon amino group of the lysine residue, but there is also a small amount of modification of the alpha amino group of the N-terminal lysine residue. The phenylalanine lyase mutant is covalently linked to the PEG modifying group through an aminoester bond, a secondary amino bond or an amide bond. Preferably, the polyethylene glycol molecule is coupled to the phenylalanine lyase mutant to form an amide bond. The modifying group of the polyethylene glycol includes but is not limited to N-hydroxysuccinimides, including but not limited to N-hydroxysuccinimide (NHS), N-hydroxysuccinimide carbonate (SC), N-hydroxysuccinimide acetate (SCM), N-hydroxysuccinimide propionate (SPA), N-hydroxysuccinimide butyrate (SBA), N-hydroxysuccinimide succinate (SS), etc., wherein the blocking group of the polyethylene glycol includes but is not limited to monomethoxy, ethoxy, glucose or galactose, preferably monomethoxy.

[0109] According to an embodiment of the present invention, the molecular weight of the polyethylene glycol used for PEG modification is 2 to 40 KDa, for example, 2 to 10 KDa or 5 to 20 KDa.

[0110] According to an embodiment of the present invention, the polyethylene glycol is a linear polyethylene glycol or a branched polyethylene glycol.

[0111] According to an embodiment of the present invention, the polyethylene glycol has a monomethoxy group or a hydroxyl group.

[0112] According to an embodiment of the present invention, the polyethylene glycol is polyethylene glycol having an active group.

[0113] According to an embodiment of the present invention, the polyethylene glycol is coupled to the lysine of the phenylalanine lyase mutant via an amide bond.

[0114] According to an embodiment of the present invention, the active group of the polyethylene glycol includes at least one of succinimidyl butyrate, succinimidyl propionate, succinimidyl acetate, succinimidyl carbonate and nitrobenzene carbonate, preferably succinimidyl propionate.

[0115] According to an embodiment of the present invention, the peptide map of the polyethylene glycol-modified phenylalanine lyase mutant has peptide segments with reduced peak areas as shown in Table 4.

[0116] According to an embodiment of the present invention, the peptide map of the polyethylene glycol-modified phenylalanine lyase mutant is shown in FIG3 .

[0117] In another aspect of the present invention, the present invention provides a method for preparing a polyethylene glycol-modified phenylalanine lyase mutant having one or more of the following characteristics:

[0118] (1) The modified molar ratio of polyethylene glycol to phenylalanine lyase mutant is (5-20):1 (polyethylene glycol: phenylalanine lyase mutant), preferably (8-16):1.

[0119] (2) The coupling reaction system is a phosphate buffer solution with a modified pH range of 7.5 to 10.5.

[0120] The method for preparing the polyethylene glycol-modified phenylalanine lyase mutant adopts multiple purification methods to obtain a high-purity polyethylene glycol-modified phenylalanine lyase mutant.

[0121] In another preferred embodiment, the modified sample is purified by methods including but not limited to molecular sieve chromatography, ion exchange chromatography, hydrophobic chromatography, tangential flow ultrafiltration, or a combination thereof, more preferably molecular sieve chromatography and tangential flow ultrafiltration.

[0122] According to an embodiment of the present invention, the molar ratio of the PEG to the phenylalanine lyase mutant is (5-20):1, for example, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1 and 20:1, and a range value between any two molar ratios, for example, 8:1-20:1.

[0123] Pharmaceutical composition

[0124] In yet another aspect, the present invention provides a pharmaceutical composition. According to an embodiment of the present invention, the pharmaceutical composition comprises: the aforementioned phenylalanine lyase mutant or the aforementioned phenylalanine lyase mutant conjugate, or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention is effective for preventing and / or treating diseases associated with high phenylalanine levels, particularly for treating phenylketonuria.

[0125] According to an embodiment of the present invention, the invention further comprises a pharmaceutically acceptable carrier.

[0126] In another aspect of the present invention, the present invention provides a use of the aforementioned phenylalanine lyase mutant, the aforementioned phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof or the aforementioned pharmaceutical composition in the preparation of a drug for preventing and / or treating high phenylalanine-related diseases.

[0127] In another aspect of the present invention, the present invention provides a use of the aforementioned phenylalanine lyase mutant, the aforementioned phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof, or the aforementioned pharmaceutical composition in preventing and / or treating high phenylalanine-related diseases.

[0128] In another aspect of the present invention, the present invention provides the aforementioned phenylalanine lyase mutant, the aforementioned phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof or the aforementioned pharmaceutical composition for use in preventing and / or treating high phenylalanine-related diseases.

[0129] According to an embodiment of the present invention, the above-mentioned uses may further include at least one of the following technical features:

[0130] According to an embodiment of the present invention, the high phenylalanine-related disease includes at least one of tumor or cancer, phenylketonuria and hyperphenylalaninemia.

[0131] According to an embodiment of the present invention, the tumor or cancer includes at least one of lung cancer, brain cancer, central nervous system cancer, colon cancer, prostate cancer, kidney cancer, head and neck cancer, ovarian cancer, uterine cancer, bladder cancer, breast cancer, pancreatic cancer, acute myeloid leukemia, acute lymphoblastic leukemia, myeloma, pediatric cancer and resistant cancer.

[0132] method

[0133] In another aspect, the present invention provides a method for preventing and / or treating a high-phenylalanine-related disease. According to an embodiment of the present invention, the method comprises administering to a subject a pharmaceutically acceptable dose of the aforementioned phenylalanine lyase mutant, the aforementioned phenylalanine lyase mutant conjugate, or a pharmaceutically acceptable salt thereof, or the aforementioned pharmaceutical composition.

[0134] The effective amount of the phenylalanine lyase mutant, phenylalanine lyase mutant conjugate, or pharmaceutically acceptable salt thereof, or pharmaceutical composition of the present invention may vary depending on the mode of administration and the severity of the disease to be treated. The preferred effective amount can be determined by one of ordinary skill in the art based on various factors (e.g., through clinical trials). Such factors include, but are not limited to, the patient's age, weight, general health, sex, diet, time of administration, drug combination, severity of the disease to be treated, route of administration, and the like. For example, depending on the requirements of the treatment situation, several divided doses may be administered daily, for example, four times a day, three times a day, twice a day, once a day, or once every other day, or several doses administered daily may be proportionally reduced; alternatively, the phenylalanine lyase mutant, phenylalanine lyase mutant conjugate, or pharmaceutically acceptable salt thereof, or pharmaceutical composition of the present invention may be administered for at least one year or longer, preferably at least one month, more preferably at least one week, and most preferably at least one day, to achieve continuous remission of the tumor or cancer.

[0135] The phenylalanine lyase mutant, phenylalanine lyase mutant conjugate, or pharmaceutically acceptable salt or pharmaceutical composition thereof of the present invention can be incorporated into applicable drugs, which can be prepared into various forms, such as liquid, semi-solid, and solid dosage forms, including but not limited to solid dosage forms, semi-solid dosage forms, liquid dosage forms, and gaseous dosage forms. Typical drugs are solution-type preparations that can be administered by injection.

[0136] According to an embodiment of the present invention, the high phenylalanine-related disease includes at least one of tumor or cancer, phenylketonuria and hyperphenylalaninemia.

[0137] According to an embodiment of the present invention, the tumor or cancer includes at least one of lung cancer, brain cancer, central nervous system cancer, colon cancer, prostate cancer, kidney cancer, head and neck cancer, ovarian cancer, uterine cancer, bladder cancer, breast cancer, pancreatic cancer, acute myeloid leukemia, acute lymphoblastic leukemia, myeloma, pediatric cancer and resistant cancer.

[0138] In another aspect, the present invention provides a method for reducing the immunogenicity of phenylalanine lyase while maintaining the enzymatic activity of the enzyme. According to an embodiment of the present invention, the method comprises: PEG-modifying the mutation site of the mutated phenylalanine lyase; the mutation site comprises at least one of E72K, Q240K, R467K, and R544K. The method of the present invention can reduce the immunogenicity of the phenylalanine lyase while maintaining a high retention rate of the phenylalanine lyase activity.

[0139] According to an embodiment of the present invention, the mutation site is located based on the amino acid sequence shown in SEQ ID NO: 1.

[0140] According to an embodiment of the present invention, the mutated phenylalanine lyase is the aforementioned phenylalanine lyase mutant.

[0141] According to an embodiment of the present invention, the mutated phenylalanine lyase has an amino acid sequence as shown in any one of SEQ ID NOs: 4 to 11, or an amino acid sequence having at least 50% homology thereto.

[0142] According to an embodiment of the present invention, the K of the phenylalanine lyase after the mutation is 72 , K 240 , K 467 and K 544 At least one amino acid site of the phenylalanine lyase is PEG-modified. Preferably, the K 72 , K 240 , K 467 and K 544 The amino acid sites have PEG modifications.

[0143] According to an embodiment of the present invention, the molecular weight of the polyethylene glycol used for PEG modification is 2 to 40 KDa, for example, 2 to 10 KDa or 5 to 20 KDa.

[0144] According to an embodiment of the present invention, the polyethylene glycol is a linear polyethylene glycol or a branched polyethylene glycol.

[0145] According to an embodiment of the present invention, the polyethylene glycol has a monomethoxy group or a hydroxyl group.

[0146] According to an embodiment of the present invention, the polyethylene glycol is polyethylene glycol having an active group.

[0147] According to an embodiment of the present invention, the polyethylene glycol is coupled to the lysine of the phenylalanine lyase mutant via an amide bond.

[0148] According to an embodiment of the present invention, the active group of the polyethylene glycol includes at least one of succinimidyl butyrate, succinimidyl propionate, succinimidyl acetate, succinimidyl carbonate and nitrobenzene carbonate, preferably succinimidyl propionate.

[0149] Below, the scheme of the present invention will be explained in conjunction with embodiment.It will be understood by those skilled in the art that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention.In the embodiment, if specific technology or conditions are not indicated, the technology or conditions described in the literature in this area or the product instructions are used.The reagents or instruments used are not indicated by the manufacturer, and are all conventional products that can be obtained by commercial purchase.

[0150] Unless otherwise indicated, the present disclosure will be practiced using conventional techniques of cell biology, molecular biology (including recombinant technology), microbiology, biochemistry and immunology, which are within the capabilities of those skilled in the art. This technology is fully explained in the literature, such as "Molecular Cloning: A Laboratory Manual," Second Edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (MJ Gait, 1984), each of which is expressly incorporated herein by reference.

[0151] Example 1: Prediction of phenylalanine lyase mutation sites

[0152] The prediction of mutation sites described in this patent is achieved through molecular modeling simulation using online or offline software such as Verify_3D, ProSA-web, and SWISS-MODEL. The mutation region is then inferred based on the results of T-cell epitope / B-cell epitope immunogenicity analysis. The feasibility of PEGylation of the mutation site is determined by the post-mutation physicochemical properties. Using the phenylalanine lyase from Anabaena variabilis as an example, the physicochemical properties of its lysine residues and mutated lysine sites are analyzed as follows:

[0153] Table 1-1: Analysis of physicochemical properties of lysine residues in phenylalanine lyase

[0154] Table 1-2: Analysis of physicochemical properties of phenylalanine lysine site mutations in phenylalanine lyase

[0155] The physicochemical properties of the lysine residues in the phenylalanine lyase sequence are shown in Table 1-1. K2 and K10 are N-terminal residues and theoretically modifiable sites. Based on their physicochemical properties, K522, K195, K413, K493 / K494 are inferred to be modifiable lysine residues. K145, K32, K301, K335, K115, and K419 are inferred to be partially modifiable sites due to their low solvent accessibility / PKa parameters or their location at the tetramer interface (interface amino acids). K109, K189, K216, K272, and K384 are inferred to be low-probability or non-modifiable sites due to their low solvent accessibility / PKa parameters and their location at the tetramer interface (interface amino acids).

[0156] Combined with the predicted immunogenicity regions, the physicochemical properties of the proposed lysine mutation sites are shown in Tables 1-2. Among them, R466K, E75K, and H250K were inferred to be partially modified or unmodifiable sites due to their low solvent accessibility / Pka parameters or their location at the tetramer polymerization interface (interface amino acids). Therefore, R544K, R467K, E72K, and H240K were selected as proposed mutation sites.

[0157] Example 2: Recombinant expression of phenylalanine lyase and its mutants

[0158] The phenylalanine lyase and its mutants of the present invention are obtained by conventional methods in the art, and the specific steps are as follows:

[0159] Nucleotide sequences encoding the amino acid sequences shown in SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6 (phenylalanine lyase or its mutants) were synthesized. Expression plasmids pET-30a-PAL, pET-30a-PAL2, pET-30a-PAL3, and pET-30a-PAL4 were constructed, respectively, by restriction endonuclease digestion and T4 DNA ligase ligation using conventional methods in the art. Escherichia coli was transformed with these four expression plasmids, and recombinant expression-engineered bacteria were obtained by resistance screening. Subsequently, the bacteria were fermented in YT medium, induced with IPTG, and harvested by centrifugation for cryopreservation.

[0160] After physical or enzymatic lysis of the fermented bacterial cells (using Tris-HCl buffer or Na₂HPO₄-NaH₂PO₄ buffer, commonly used in enzyme purification processes, with the pH adjusted to 8.0±1.0), the phenylalanine lyase or its mutant is distributed in a soluble form in the lysate supernatant. Insoluble lysate fragments are removed by centrifugation. The supernatant obtained after centrifugation is then subjected to fractional precipitation with (NH₄)₂SO₄ to enrich the phenylalanine lyase and reduce host protein impurities. Centrifugation is then repeated to obtain the precipitate of the phenylalanine lyase or its mutant. After dissolution, the precipitate is purified by hydrophobic chromatography to remove host protein impurities. The eluate is then finely purified by ion exchange chromatography to remove high- and low-molecular-weight related proteins. The hydrophobic chromatography medium is phenylyl or butyl sepharose, and the ion exchange chromatography medium is Source 30Q or 15Q. The resulting phenylalanine lyase and its mutants are designated PAL, PAL2, PAL3, and PAL4, respectively, based on the number of point mutations present. The intermediate product was then assessed by SDS-PAGE and SEC-HPLC, respectively, to ensure a purity of no less than 95% and a high-molecular-weight polymer content of no more than 1.0%. The SDS-PAGE and SEC-HPLC assay profiles of the phenylalanine lyase mutant PAL4 protein are shown in Figures 1A, 1B, and 2, respectively. Figure 1A shows, from left to right, the intermediate molecular weight marker (from top to bottom, 97.4 kDa, 66.2 kDa, 43.0 kDa, 31.0 kDa, 22.0 kDa, 14.4 kDa), PAL2, PAL3, and PAL4; Figure 1B shows, from left to right, the intermediate molecular weight marker (from top to bottom, 97.4 kDa, 66.2 kDa, 43.0 kDa, 31.0 kDa, 22.0 kDa, 14.4 kDa), PAL, and PAL4. Figure 2 shows the SEC-HPLC assay profiles of the high and low molecular weight content of the PAL4 mutant.

[0161] Example 2: Preparation of polyethylene glycol conjugates of phenylalanine lyase and its mutants and their average degree of modification

[0162] 1. The PAL, PAL2, PAL3, and PAL4 proteins (phenylalanine lyase and its mutants) prepared in Example 1 were concentrated by ultrafiltration and buffer exchange. The phenylalanine lyase and its mutants were added to a 100 mmol / L Na2HPO4-NaH2PO4 buffer with a pH of 7.5-10.5, and the content was 20 mg / L. PEG-SPA-5K at different mass ratios or molar ratios (see Table 1 for details) was added and the modification reaction was stirred at room temperature for 1 hour. The obtained modified phenylalanine lyase and its mutant products were subjected to ultrafiltration or molecular exclusion to remove free PEG and NHS, and the PEG-modified phenylalanine lyase and its mutant products were concentrated to above 5 mg / ml. The protein content was determined by the Lowry method, and the products were sterile filtered to obtain polyethylene glycol conjugates of phenylalanine lyase and its mutants (referred to as conjugates). They were named PAL, PAL2, PAL3, and PAL4 according to their mutation sites, and conjugates with different feed ratios were named based on the number of mutation sites and the molecular weight of PEG. The specific names are shown in Table 1.

[0163] 2. Detection of the average degree of modification of PEGylated conjugates of phenylalanine lyase and its mutants

[0164] Taking advantage of the fact that the concentration of protein (phenylalanine lyase or its mutant) in the solution is linearly related to its differential refractive index (RI) and ultraviolet (UV) absorption, and that polyethylene glycol has no UV absorption but a linear relationship between its concentration and its differential refractive index (RI) absorption value, and that the differential refractive index and UV absorption of protein and PEG do not affect each other, a SEC-HPLC differential refractive index-UV detector can be used to establish a standard curve of protein and PEG content-absorption peak area, and the content of protein and polyethylene glycol in the test sample can be measured. Combined with the relative molecular weights of protein and polyethylene glycol, the molar content ratio of protein to polyethylene glycol molecules can be calculated as a representation of the average degree of modification.

[0165] The calculation formula is as follows:

[0166] Wherein, M represents relative molecular mass, PL represents PEGylated phenylalanine lyase, PAL represents phenylalanine lyase or its mutant, PEG represents polyethylene glycol, (RI) represents differential peak area, and (UV) represents ultraviolet peak area.

[0167] Table 1: Average modification degree of phenylalanine lyase or its mutants at different feed ratios

[0168] As shown above, compared to PAL, PAL2, PAL3, and PAL4 have higher average modification degrees. Especially under conditions of equal feed ratios, the average modification degree of PAL4 > that of PAL3 > that of PAL2 > that of PAL. Therefore, this suggests that the number of mutation sites can effectively increase the average modification degree under equal feed ratios, and that the average modification degree of different structures is correlated with the number of mutation sites under equal feed ratios.

[0169] Example 3: Specific Enzyme Activity of Phenylalanine Lyase, Its Mutants, and Its Polyethylene Glycol Conjugates

[0170] Phenylalanine lyase specifically catalyzes the conversion of phenylalanine to trans-cinnamic acid, releasing ammonia. Trans-cinnamic acid has a maximum absorption wavelength of 290 nm. One unit of enzyme activity is defined as the amount of enzyme required to generate 1 μmol of trans-cinnamic acid per minute at room temperature (25°C) in 100 mmol / L Tris-HCl (pH 8.5) buffer.

[0171] 1. Specific activity of phenylalanine lyase mutants

[0172] The specific enzyme activity of the phenylalanine lyase prepared in Example 1 and its mutants (i.e., PAL, PAL2, PAL3, and PAL4 proteins) was determined. The specific assay method was as follows: an appropriate amount of the test sample was diluted to 0.4 mg / ml using activity assay buffer (100 mmol / L Tris-HCl, pH 8.0); 2.9 ml of substrate solution (100 mmol / L Tris-HCl, 45 mmol / L Phe, pH 8.0) was placed in a cuvette, 0.1 ml of the diluted test sample solution was added, and the mixture was immediately mixed; the change in absorbance per minute was recorded at a wavelength of 290 nm, and the specific enzyme activity was calculated according to the formula.

[0173] Enzyme activity (U / mg) = (A S -A O )VN×10 6 / εLTV1

[0174] Among them, A S 、A O where ε represents the absorbance of trans-cinnamic acid at the start and end of the reaction, respectively; V is the total volume of the reaction system (L); L is the optical path length of the cuvette (cm); ε is the molar extinction coefficient of trans-cinnamic acid (10238.1 L / (mol·cm)); T is the reaction time (min); N is the dilution factor of the test sample; and V1 is the volume of the test sample (ml).

[0175] Specific results are shown in Table 2. The enzyme activity retention rate of the phenylalanine lyase mutant was obtained by comparing the enzyme specific activity of the phenylalanine lyase mutant with the enzyme specific activity of the phenylalanine lyase.

[0176] Table 2 Specific activity of phenylalanine lyase mutants

[0177] As shown in Table 2, there was no significant difference in the enzyme specific activities of PAL, PAL2, PAL3 and PAL4 proteins. Compared with PAL protein, the enzyme activity retention rate of the phenylalanine lyase mutants (PAL2, PAL3 or PAL4 protein) was above 90%.

[0178] 2. Specific activity of phenylalanine lyase mutant polyethylene glycol conjugates

[0179] The enzyme activity retention rate of the polyethylene glycol conjugates of phenylalanine lyase and its mutants prepared in step 1 of Example 2 was determined by referring to the method in step 1 of this example. The enzyme activity retention rate was obtained by comparing the enzyme activity of the conjugate with the enzyme activity before PEG modification (e.g., enzyme activity retention rate of PL5-1 = enzyme activity of PL5-1 / enzyme activity of PAL protein). See Table 3 for details.

[0180] Table 3: Specific activity of PEGylated phenylalanine lyase mutant enzymes

[0181] As shown in Table 3, the enzyme activity retention rates of the polyethylene glycol conjugates of the phenylalanine lyase mutants of the present invention after targeted saturation modification were all above 65%, and the enzyme activity retention rate of the polyethylene glycol conjugates of the phenylalanine lyase mutants after targeted saturation modification at four mutation sites was above 80%. It was further found that although the phenylalanine lyase (unmutated structure) could achieve a similar degree of modification by overdosing, its activity retention rate was significantly reduced, only 47% of the pre-modification level. This further demonstrates that in order to achieve the goal of increasing the average degree of modification to saturation, the PEGylated phenylalanine lyase mutants have an average degree of modification and enzyme activity retention rate that are unattainable by the unmutated structure.

[0182] Example 4: Study on modification sites of polyethylene glycol conjugates of PEGylated phenylalanine lyase and its mutants

[0183] PEGylated phenylalanine lyase and its mutants are produced by covalently binding PEG to the amino side chain of a lysine residue or the amino group of the N-terminal amino acid in the amino acid sequence. Trypsin and lysyl endopeptidase cannot recognize and cleave PEG-modified lysines. Therefore, the modification site can be inferred by comparing the peptides before and after modification. The inventors used trypsin and Lys-C to double-cleave PEGylated phenylalanine lyase and its mutants (PL54-5 prepared in step 1 of Example 2) before and after covalent PEG coupling. LC-MS analysis of the modification sites of the PEGylated phenylalanine lyase mutants is shown in Table 4 and Figure 3.

[0184] The results showed that after the PAL4 protein was modified with polyethylene glycol and coupled to obtain PL54-5, the peptide fragments or adjacent peptide fragments at the mutation site disappeared completely or had a reduced response after lysine cleavage, and the four mutation sites (K 72 , K 240 , K 467 and K 544 ) were completely modified, or the modification rate was higher than 90%.

[0185] Table 4: Comparison of enzyme-cleaved peptide maps before and after PL54 modification

[0186] Example 5: Multiple in vivo pharmacokinetic / immunogenicity studies of polyethylene glycol conjugates of phenylalanine lyase or its mutants in SD rats

[0187] In order to evaluate the PEGylated conjugates of phenylalanine lyase or its mutants with different average modification degrees, the inventors selected SD rats and divided them into 4 groups, with 6 rats in each group. PL54-1 and PL54-5 (average modification degrees of 10.54 and 13.60, respectively) and PL5-1 and PL5-5 (average modification degrees of 8.2 and 10.53, respectively) in Table 3 of Example 2 were subcutaneously injected at 2 mg / kg once a week for 4 times. Blood was collected on D1 (first day), D3 (third day), D7 (seventh day) of the first administration, as well as on D3 and D7 of each administration. The levels of PL54-1, PL54-5, PL5-1 and PL5-5 in the serum of rats in each group were detected by double antibody sandwich ELISA to evaluate the blood drug maintenance after multiple administration. The results were also analyzed by indirect ELISA (coated with PEG-BSA, added with positive rat Anti-PEG Abs / test serum sample, HRP-Anti Rats The anti-PEG-IgM / IgG antibody titers in the serum of each group of rats were measured using a bridging ELISA (coating with PAL protein, adding positive sheep anti-PAL Abs / acidified serum, and developing the biotin-PAL reaction). The blood drug test results are shown in Figure 4, and the antibody test results after administration are shown in Figures 4 and 5.

[0188] As shown in Figure 4, after the first administration, the concentration of PEGylated conjugates of phenylalanine lyase or its mutants in rat serum was 30-40 μg / ml, with no significant difference; after the second administration, accelerated clearance occurred, and the blood drug maintenance effect of PL54-5 was better than that of PL5-1 and PL5-5; 3 days after the last administration, only 3 / 6 and 1 / 6 rats with PL5-1 and PL5-5 were detected in the blood, respectively, and the blood drug concentration of some animals was still low, while 4 / 6 rats with PL54-5 (average modification degree 13.6) had a higher blood drug maintenance, with a blood drug concentration of 20-41 μg / ml, and the blood drug concentration could be maintained in the range of 3.2-3.9 μg / ml 7 days after administration.

[0189] As shown in Figure 5A, after multiple administration, at a serum dilution of 1:20, the anti-PEG-IgM antibodies and anti-PEG-IgG antibodies in the serum of the four groups of rats were all positive, and there were differences in the antibody strength. However, there was no obvious correlation between the antibody strength and the PEG dose (average modification degree). The antibody strength of PL5-1 / PL54-1 with low average modification degree and incomplete encapsulation and PL5-5 with decreased supersaturated modification activity was stronger than that of PL54-5.

[0190] As shown in Figure 5B, at a serum dilution of 1:10, PL54-1 and PL54-5 showed very weak anti-PAL protein antibody positivity after the first dose. Antibody titers generally decreased over the course of four doses, with 4 / 6 and 1 / 6, respectively, showing very weak antibody positivity by day 7 after the fourth dose. PL5-1 showed significant anti-PAL protein antibody positivity after the first dose. As the number of doses increased, by day 7 after the fourth dose, the positive rate reached 6 / 6, with 3 / 6 showing extremely significant positivity. PL5-5 showed similar progression to PL5-1, with a positive rate of 5 / 6, with 3 / 6 showing significant or extremely significant positivity by day 7 after the fourth dose. Furthermore, it can be seen that the accelerated clearance of the drug from the blood of rats correlates with antibody strength.

[0191] Example 6: Pah enu Single-dose pharmacodynamics and pharmacokinetics study in mice

[0192] Phenylalanine hydroxylase (PAH) is the core of phenylalanine metabolism in animals, converting phenylalanine into tyrosine. Defects in this gene are the basis of phenylketonuria. By inducing a missense mutation through ENU (reference: Lukas Villiger et al., Treatment of a metabolic liver disease by in vivo genome base editing in adult mice; missense mutation F263S), PAH catalytic activity is severely reduced in homozygous mice, and the phenylalanine content in the serum accumulates and cannot be metabolized, which is significantly higher than that of normal wild-type mice. These mice can be used as phenylketonuria animal model mice (abbreviated as Pah) for this drug study. enu mice or model mice).

[0193] In order to evaluate the polyethylene glycol conjugate PL54 for the targeted saturation modification of phenylalanine lyase mutants, six Pah enu Mice were divided into three groups, each containing two mice. PL54-5 (average degree of modification 13.60, specific enzyme activity 1.27 U / mg) listed in Table 3 of Example 2 was administered to phenylketonuria model mice at three doses: low, medium, and high. The low, medium, and high dose groups received 0.5 mg / kg, 1.5 mg / kg, and 4.5 mg / kg, respectively, by subcutaneous injection. Blood was collected from each group of mice 1 hour before administration and 1, 3, 5, 7, 10, and 14 days after administration. The serum PL54-5 content was measured by double-antibody sandwich ELISA (see Example 5 for details).

[0194] As shown in Table 5, the subcutaneous injection of Pah enu In mice, the blood drug concentration is directly proportional to the dosage, and the blood drug level lasts for 5 to 7 days.

[0195] Table 5 Pah enu Drug concentration in serum of mice after single administration

[0196] Example 7: Pah enu Study on the pharmacokinetic, pharmacodynamic and immunogenicity of multiple-dose mice

[0197] To evaluate the polyethylene glycol conjugate PL54 for the targeted saturation modification of phenylalanine lyase mutants, 27 Pah enuThe mice were divided into 5 groups (4 experimental groups and 1 control group), 6 in each group, and PL54-5 (average modification degree 13.60, enzyme specific activity 1.27 U / mg) in Table 3 of Example 2 was administered to phenylketonuria animal model mice at three doses: low, medium, and high. The low, medium, and high dose groups were administered 0.5 mg / kg, 1.5 mg / kg, and 4.5 mg / kg, respectively, by subcutaneous injection, and the high dose group was administered 4.5 mg / kg at the same time as the intramuscular administration group, once a week; the control group was subcutaneously administered phosphate buffered saline as a placebo, once a week. Among them, blood was collected from each group of mice 1 hour before administration, 2 days, 5 days and 7 days after administration, and the PL54-5 content, phenylalanine concentration changes (reference: Judy Peat et al., Determination of Phenylalanine and Tyrosine by High Performance Liqiud Chromatography-Tandem Mass Spectrometry) and Anti-PEG-IgM / IgG antibody titer in the serum were detected by double antibody sandwich ELISA (see Example 5 for details) and the pharmacokinetics were evaluated, as shown in Figures 6 to 9.

[0198] (1) Pah enu Multiple-dose pharmacodynamic study in mice

[0199] Figure 6 shows changes in serum phenylalanine concentrations in Pahenu mice after multiple administration of different doses. The results indicate that subcutaneous administration of medium and high doses (1.5 mg / kg and 4.5 mg / kg) effectively reduced serum phenylalanine levels, with the medium dose reducing levels by approximately 30% to 50%. The high dose reduced serum phenylalanine levels to below the detection limit within two days of the first administration, and the drug's efficacy was maintained for 5 to 7 days after the initial administration. After five repeated doses, the maintenance of efficacy was similar to the reduction in serum phenylalanine levels after the initial administration, with the medium-dose group reducing levels by approximately 75% within two days and the high-dose group reducing levels by over 90%. The efficacy after intramuscular and subcutaneous administration was consistent.

[0200] (2) Pah enu Pharmacokinetics in serum of mice after multiple administration

[0201] Figure 7 shows changes in blood concentrations in Pahenu mice after multiple administration of different doses. The results show that two days after subcutaneous administration, blood concentrations were positively correlated with the dose. After five weeks of continuous administration, blood concentrations and serum phenylalanine levels decreased in a dose-dependent manner, demonstrating a favorable PK-PD relationship. High-dose intramuscular administration resulted in higher blood concentrations than subcutaneous administration, suggesting that intramuscular administration may enhance bioavailability.

[0202] (3) Pahenu Immunogenicity study after multiple administration in mice

[0203] Figures 8 and 9 show the titers of anti-PEG and anti-PAL antibodies in Pahenu mice after multiple administration of different doses. The results show that anti-PEG antibodies were positive in all dose groups, with a positive correlation between antibody titers and dose. IgG and IgM antibody S / N values ​​decreased with increasing dose frequency, with a more significant decrease in the high-dose group. Anti-PAL4 protein antibodies were negative after subcutaneous administration, but weakly positive after intramuscular administration.

[0204] Example 8: Comparative study on the immunogenicity of conjugates of polyethylene glycol with different molecular weights in rats

[0205] Polyethylene glycol conjugates of phenylalanine lyase or its mutants with different structures and modifier molecular weights were prepared using the method of Example 2, namely PL20, PL24, and PL54. The phenylalanine lyase of PL20 has the amino acid sequence shown in SEQ ID NO: 1 and the molecular weight of polyethylene glycol is 20K, the phenylalanine lyase of PL24 has the amino acid sequence shown in SEQ ID NO: 6 and the molecular weight of polyethylene glycol is 2K, and the phenylalanine lyase of PL54 has the amino acid sequence shown in SEQ ID NO: 6 and the molecular weight of polyethylene glycol is 5K.

[0206] To evaluate the immunogenicity of PL20, PL24, and PL54 in animals, normal rats were selected and divided into three groups, each consisting of 6 rats of equal sex. A dose of 0.75 mg / kg was administered subcutaneously. The three groups were administered PL54 (average degree of modification 13.6, 1.27 U / mg), PL24 (average degree of modification 13.3, 0.96 U / mg), and PL20 (average degree of modification 7.6, 1.14 U / mg), respectively. The administration was continued for 7 times, once a week. Blood was collected 7 days after administration, and anti-PEG-IgG antibodies and anti-PAL4 protein antibodies in the serum were detected by ELISA (see Example 5 for details). The results are shown in Table 6. In the table, 1-7 are 7 days after the first administration, 7-7 are 7 days after the seventh administration, It represents the average OD value of the antibody detection ELISA method, and the positive rate represents the number of antibody-positive animals / all animals in the group.

[0207] Table 6: Antibody titers of rat antibodies conjugated with polyethylene glycol of different molecular weights after multiple administration

[0208] As shown in Table 6, the anti-PEG-IgG antibody titer in rats of PL20 groups was higher than that of PL24 and PL54 groups 7 days after the 7th administration; no anti-PAL4 protein antibody was detected in the animals of PL54 groups 7 days after the 7th administration, which was better than PL20 and PL24.

[0209] Example 9: Pharmacokinetic study of multiple subcutaneous / intravenous administration in beagle dogs

[0210] The pharmacokinetics of multiple subcutaneous / intravenous administration were evaluated in dogs. Six beagle dogs were divided equally into two groups, a subcutaneous administration group and an intravenous administration group. The drug was PL54-5 (average degree of modification 13.60, enzyme specific activity 1.27 U / mg) listed in Table 3 of Example 2. The dose was 2 mg / kg once a week. Blood was collected from the beagle dogs in both groups on days 1, 3, 5, and 7 after the first administration and on days 1 and 3 after each subsequent administration. The double antibody sandwich ELISA method (see Example 5 for details) was used to detect the blood drug concentration in the serum. The blood drug concentration analysis results are shown in Figure 10.

[0211] As shown in Figure 10, the time to peak blood drug after single subcutaneous / intravenous administration was 3 days and 1 day after administration, respectively; the bioavailability of subcutaneous administration relative to intravenous administration was 64.4%; after multiple administration, 1 / 3 of the dogs with subcutaneous administration and 2 / 3 of the dogs with intravenous administration showed accelerated blood drug clearance.

[0212] Example 10: Pah enu Comparative study of the pharmacodynamics and immunogenicity of multiple-dose polyethylene glycol conjugate PL54-5 and Pegvaliase in mice

[0213] In order to evaluate the pharmacodynamics and immunogenicity differences between PL54-5, a polyethylene glycol conjugate of a phenylalanine lyase mutant, and Pegvaliase (a marketed drug), 8 Pah enuMice were divided into two groups, each with four mice, and were given PL54-5 (average degree of modification 13.60, enzyme specific activity 1.27 U / mg) and Pegvaliase injection (BioMarin production, purchase batch number L161239, specification 20 mg / mL / vial) in Table 3 of Example 2, respectively. The dosage was 3.0 mg / kg, subcutaneously administered once a week for 4 consecutive weeks. Among them, blood was collected from each group of mice before administration, 3 days after each administration, and 7 days after each administration. The changes in serum phenylalanine concentration (reference: Judy Peat et al., Determination of Phenylalanine and Tyrosine by High Performance Liqiud Chromatography-Tandem Mass Spectrometry) and the anti-PEG-IgM / IgG antibody titer of each animal at the end of the experiment (see Example 5 for details) were used to evaluate the pharmacodynamic and immunogenic differences, as shown in Figures 11 and 12.

[0214] (1) Pah enu Comparison of multiple-dose pharmacodynamic studies in mice

[0215] Pah enu Figure 11 shows changes in serum phenylalanine concentrations in mice after multiple administration of PL54-5 and Pegvaliase. The results show that at the same dose (3 mg / kg), both PL54-5 and Pegvaliase exhibited similar phenylalanine-lowering effects on Day 3 of the first administration, with both returning to baseline levels on Day 7. However, from Day 3 to Day 4 of the second to fourth administration, PL54 maintained its phenylalanine-lowering effect, similar to that observed with the initial administration, while Pegvaliase lost its phenylalanine-lowering effect. Long-term administration of PL54-5 significantly outperformed Pegvaliase in lowering phenylalanine.

[0216] (2) Pah enu Immunogenicity study after multiple administration in mice

[0217] Pah enu The anti-PEG antibody titers of mice after multiple administration of PL54-5 and Pegvaliase are shown in Figure 12. The results showed that after 4 consecutive weeks of administration of 3 mg / kg PL54-5 and 3 mg / kg Pegvaliase, the anti-PEG IgG and IgM antibody S / N values ​​of the Pegvaliase group were significantly higher than those of the PL54-5 group. enu The immunogenicity of the drug after long-term administration in mice was significantly lower than that of Pegvaliase.

[0218] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.

[0219] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. A phenylalanine lyase mutant, characterized in that: Compared with the amino acid sequence of phenylalanine lyase, the phenylalanine lyase mutant has the following mutation sites: At least one of the 72nd, 240th, 467th, and 544th.

2. The phenylalanine lyase mutant according to claim 1, characterized in that The mutation site is located based on the amino acid sequence shown in SEQ ID NO:

1.

3. The phenylalanine lyase mutant according to claim 1, characterized in that The phenylalanine lyase has an amino acid sequence as shown in SEQ ID NO: 1-3 or an amino acid sequence having at least 50% homology thereto.

4. The phenylalanine lyase mutant according to claim 1, characterized in that The mutation site of the phenylalanine lyase mutant is an amino acid that can bind to a modification group.

5. The phenylalanine lyase mutant according to claim 4, characterized in that The amino acid to which the modifying group can be attached is lysine.

6. The phenylalanine lyase mutant according to claim 1, characterized in that The mutation site of the phenylalanine lyase mutant is selected from the amino acid site of ASA≥60% or RSA≥30%.

7. The phenylalanine lyase mutant according to claim 1, characterized in that The mutation site of the phenylalanine lyase mutant is selected from an amino acid site with pKa>9.

0.

8. The phenylalanine lyase mutant according to claim 1, characterized in that Compared with the amino acid sequence shown in any one of SEQ ID NOs: 1 to 2, the phenylalanine lyase mutant includes at least one mutation site among E72K, Q240K, R467K and R544K.

9. The phenylalanine lyase mutant according to claim 1, characterized in that Compared with the amino acid sequence shown in SEQ ID NO: 3, the phenylalanine lyase mutant includes at least one mutation site among E72K, R467K and R544K.

10. The phenylalanine lyase mutant according to claim 1, characterized in that Compared with the amino acid sequence shown in any one of SEQ ID NOs: 1 to 2, the phenylalanine lyase mutant has the following mutation sites: 1) R467K and R544K; or 2) E72K, R467K and R544K; or 3)E72K, Q240K, R467K and R544K.

11. The phenylalanine lyase mutant according to claim 1, characterized in that Compared with the amino acid sequence shown in SEQ ID NO: 3, the phenylalanine lyase mutant has the following mutation sites: 1) R467K and R544K; or 2)E72K, R467K and R544K.

12. The phenylalanine lyase mutant according to claim 1, characterized in that The phenylalanine lyase mutant has an amino acid sequence as shown in any one of SEQ ID NOs: 4 to 11 or an amino acid sequence having at least 50% homology thereto.

13. A nucleic acid molecule, characterized in that Encoding the phenylalanine lyase mutant according to any one of claims 1 to 12; Optionally, the nucleic acid molecule is DNA.

14. An expression vector, characterized in that: Carrying the nucleic acid molecule according to claim 13; Optionally, the expression vector is a eukaryotic expression vector, a prokaryotic expression vector, a virus or a bacteriophage; Preferably, the expression vector is a lentiviral expression vector.

15. A recombinant cell, characterized in that include: Carrying the nucleic acid molecule according to claim 13 or the expression vector according to claim 14; or Expressing the phenylalanine lyase mutant according to any one of claims 1 to 12; Optionally, the recombinant cell is obtained by introducing the expression vector of claim 14 into a host cell.

16. A phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof, characterized in that: include: The phenylalanine lyase mutant according to any one of claims 1 to 12; A modifying group is connected to the phenylalanine lyase mutant.

17. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 16, characterized in that: The modifying group is polyethylene glycol.

18. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 17, characterized in that: The molecular weight of the polyethylene glycol is 2-40 KDa.

19. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 17, characterized in that: The molecular weight of the polyethylene glycol is 2 to 10 KDa.

20. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 17, characterized in that: The polyethylene glycol is a linear polyethylene glycol or a branched polyethylene glycol.

21. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 17, characterized in that: The polyethylene glycol has a monomethoxy group or a hydroxyl group.

22. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 17, characterized in that: The polyethylene glycol is polyethylene glycol having an active group.

23. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 17, characterized in that: The active group of the polyethylene glycol includes at least one of succinimidyl butyrate, succinimidyl propionate, succinimidyl acetate, succinimidyl carbonate and nitrobenzene carbonate.

24. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 17, characterized in that: The active group of the polyethylene glycol is succinimidyl propionate.

25. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 16, characterized in that: The modifying group and the lysine of the phenylalanine lyase mutant are coupled via an amide bond.

26. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 16, characterized in that: The coupling rate of lysine in the phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof modified by the modifying group is not less than 50%.

27. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 16, characterized in that: The coupling rate of lysine at the mutation site in the phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof modified by the modifying group is not less than 80%.

28. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 16, characterized in that: The molar ratio of the modification group to the phenylalanine lyase mutant is (5-20):

1.

29. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 16, characterized in that: The peptide map of the phenylalanine lyase mutant conjugate has peptide segments with reduced peak areas as shown in Table 4.

30. The phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to claim 16, characterized in that: The peptide map of the phenylalanine lyase mutant conjugate is shown in FIG3 .

31. A polyethylene glycol-modified phenylalanine lyase mutant, characterized in that: At least the following amino acid sites in the phenylalanine lyase mutant are PEG-modified: 72 , K 240 , K 467 and K 544 .

32. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 31, characterized in that The molecular weight of the polyethylene glycol used for PEG modification is 2 to 40 KDa.

33. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 31, characterized in that The molecular weight of the polyethylene glycol used for PEG modification is 2 to 10 KDa.

34. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 32 or 33, characterized in that: The polyethylene glycol is a linear polyethylene glycol or a branched polyethylene glycol.

35. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 32 or 33, characterized in that: The polyethylene glycol has a monomethoxy group or a hydroxyl group.

36. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 32 or 33, characterized in that: The polyethylene glycol is polyethylene glycol having an active group.

37. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 32 or 33, characterized in that: The polyethylene glycol is coupled to the lysine of the phenylalanine lyase mutant via an amide bond.

38. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 32 or 33, characterized in that: The active group of the polyethylene glycol includes at least one of succinimidyl butyrate, succinimidyl propionate, succinimidyl acetate, succinimidyl carbonate and nitrobenzene carbonate.

39. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 32 or 33, characterized in that: The active group of the polyethylene glycol is succinimidyl propionate.

40. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 31, characterized in that The molar ratio of the PEG to the phenylalanine lyase mutant is (5-20):

1.

41. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 31, characterized in that The phenylalanine lyase mutant is the phenylalanine lyase mutant as defined in any one of claims 1 to 12.

42. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 31, characterized in that The phenylalanine lyase mutant has an amino acid sequence as shown in any one of SEQ ID NOs: 4 to 11 or an amino acid sequence having at least 50% homology thereto.

43. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 31, characterized in that The peptide map of the polyethylene glycol-modified phenylalanine lyase mutant has peptide segments with reduced peak areas as shown in Table 4.

44. The polyethylene glycol-modified phenylalanine lyase mutant according to claim 31, characterized in that The peptide map of the polyethylene glycol-modified phenylalanine lyase mutant is shown in FIG3 .

45. A pharmaceutical composition, characterized in that include: The phenylalanine lyase mutant according to any one of claims 1 to 12, the phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 16 to 30, or the polyethylene glycol-modified phenylalanine lyase mutant according to any one of claims 31 to 44; Optionally, a pharmaceutically acceptable carrier is further included.

46. ​​Use of the phenylalanine lyase mutant according to any one of claims 1 to 12, the phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 16 to 30, the polyethylene glycol-modified phenylalanine lyase mutant according to any one of claims 31 to 44, or the pharmaceutical composition according to claim 45 in the preparation of a drug for preventing and / or treating a high phenylalanine-related disease; Optionally, the high phenylalanine-related disease comprises at least one of a tumor or cancer, phenylketonuria and hyperphenylalaninemia; Optionally, the tumor or cancer comprises at least one of lung cancer, brain cancer, central nervous system cancer, colon cancer, prostate cancer, kidney cancer, head and neck cancer, ovarian cancer, uterine cancer, bladder cancer, breast cancer, pancreatic cancer, acute myeloid leukemia, acute lymphoblastic leukemia, myeloma, pediatric cancer and resistant cancer.

47. Use of the phenylalanine lyase mutant according to any one of claims 1 to 12, the phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 16 to 30, the polyethylene glycol-modified phenylalanine lyase mutant according to any one of claims 31 to 44, or the pharmaceutical composition according to claim 45 in preventing and / or treating high phenylalanine-related diseases; Optionally, the high phenylalanine-related disease comprises at least one of a tumor or cancer, phenylketonuria and hyperphenylalaninemia; Optionally, the tumor or cancer comprises at least one of lung cancer, brain cancer, central nervous system cancer, colon cancer, prostate cancer, kidney cancer, head and neck cancer, ovarian cancer, uterine cancer, bladder cancer, breast cancer, pancreatic cancer, acute myeloid leukemia, acute lymphoblastic leukemia, myeloma, pediatric cancer and resistant cancer.

48. The phenylalanine lyase mutant according to any one of claims 1 to 12, the phenylalanine lyase mutant conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 16 to 30, the polyethylene glycol-modified phenylalanine lyase mutant according to any one of claims 31 to 44, or the pharmaceutical composition according to claim 45, for preventing and / or treating a high phenylalanine-related disease; Optionally, the high phenylalanine-related disease comprises at least one of a tumor or cancer, phenylketonuria and hyperphenylalaninemia; Optionally, the tumor or cancer comprises at least one of lung cancer, brain cancer, central nervous system cancer, colon cancer, prostate cancer, kidney cancer, head and neck cancer, ovarian cancer, uterine cancer, bladder cancer, breast cancer, pancreatic cancer, acute myeloid leukemia, acute lymphoblastic leukemia, myeloma, pediatric cancer and resistant cancer.

49. A method for preventing and / or treating a high phenylalanine-related disease, characterized in that: include: Administering to a subject a pharmaceutically acceptable dose of the phenylalanine lyase mutant according to any one of claims 1 to 12, the phenylalanine lyase mutant conjugate according to any one of claims 16 to 30 or a pharmaceutically acceptable salt thereof, the polyethylene glycol-modified phenylalanine lyase mutant according to any one of claims 31 to 44, or the pharmaceutical composition according to claim 45; Optionally, the high phenylalanine-related disease comprises at least one of a tumor or cancer, phenylketonuria and hyperphenylalaninemia; Optionally, the tumor or cancer comprises at least one of lung cancer, brain cancer, central nervous system cancer, colon cancer, prostate cancer, kidney cancer, head and neck cancer, ovarian cancer, uterine cancer, bladder cancer, breast cancer, pancreatic cancer, acute myeloid leukemia, acute lymphoblastic leukemia, myeloma, pediatric cancer and resistant cancer.

50. A method for reducing the immunogenicity of phenylalanine lyase while maintaining the enzymatic activity of phenylalanine lyase, characterized in that: include: The mutated site of the phenylalanine lyase is subjected to PEG modification; The mutation sites include at least one of E72K, Q240K, R467K and R544K.

51. The method according to claim 50, characterized in that The mutation site is located based on the amino acid sequence shown in SEQ ID NO:

1.

52. The method according to claim 50, characterized in that The mutated phenylalanine lyase is the phenylalanine lyase mutant according to any one of claims 1 to 12.

53. The method according to claim 50, characterized in that The mutated phenylalanine lyase has an amino acid sequence as shown in any one of SEQ ID NOs: 4 to 11 or an amino acid sequence having at least 50% homology thereto.

54. The method according to claim 50, characterized in that The K of the mutated phenylalanine lyase 72 , K 240 , K 467 and K 544 The amino acid sites have PEG modifications.

55. The method according to claim 50, characterized in that The molecular weight of the polyethylene glycol used for PEG modification is 2 to 40 KDa.

56. The method of claim 50, wherein: The molecular weight of the polyethylene glycol used for PEG modification is 2 to 10 KDa.

57. The method according to claim 55 or 56, characterized in that The polyethylene glycol is a linear polyethylene glycol or a branched polyethylene glycol.

58. The method according to claim 55 or 56, characterized in that The polyethylene glycol has a monomethoxy group or a hydroxyl group.

59. The method according to claim 55 or 56, characterized in that The polyethylene glycol is polyethylene glycol having an active group.

60. The method according to claim 55 or 56, characterized in that The polyethylene glycol is coupled to the lysine of the phenylalanine lyase mutant via an amide bond.

61. The method according to claim 55 or 56, characterized in that The active group of the polyethylene glycol includes at least one of succinimidyl butyrate, succinimidyl propionate, succinimidyl acetate, succinimidyl carbonate and nitrobenzene carbonate.

62. The method according to claim 55 or 56, characterized in that The active group of the polyethylene glycol is succinimidyl propionate.

Citation Information

Patent Citations

  • Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions

    CN101842482A

  • Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof

    CN102753566A

  • Phenylalanine deaminase mutant with improved enzyme activity

    CN106636048A

  • Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof

    CN106834261A

  • Novel phenylalanine ammonialyase with high expression

    CN115873837A